Immunosuppressive treatment of acquired aplastic anemia and immune-mediated bone marrow failure syndromes

International Journal of Hematology

Volumn 75, Issue 2, 2002, Pages 129-140

  Young, Neal S ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Antilymphocyte globulin; Antithymocyte globulin; Autoimmunity; Bone marrow; Cyclosporine; Hematopoiesis

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; LYMPHOCYTE ANTIBODY; THROMBOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

APLASTIC ANEMIA; AUTOIMMUNITY; BLOOD CELL COUNT; BLOOD TRANSFUSION; BONE MARROW DEPRESSION; CELL DESTRUCTION; CLONAL VARIATION; DRUG MEGADOSE; DRUG TOLERABILITY; HEMATOPOIETIC CELL; HISTOCOMPATIBILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MYELODYSPLASIA; PATHOPHYSIOLOGY; REVIEW; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; BONE MARROW DISEASE; DRUG COMBINATION; IMMUNOLOGY; METHODOLOGY; SYNDROME;

ANEMIA, APLASTIC; BONE MARROW DISEASES; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; STEM CELL TRANSPLANTATION; SYNDROME;

EID: 0036463753     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-3019(01)00687-5     Document Type: Note

References (129)

1. Frickhofen N, Rosenfeld SJ. Immunosuppressive treatment of aplastic anemia with antithymocyte globulin and cyclosporine. Semin Hematol. 2000;37:56-68.
2. Bacigalupo A, Brand R, Oneto R, et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy - The European Group for Blood and Marrow Transplantation experience. Semin Hematol. 2000;37:69-80.
3. Marsh JCW. Results of immunosuppression in aplastic anaemia. Acta Haematol. 2000;103:26-32.
4. Kojima S, Nakao S, Tomonaga M, et al. Consensus conference on the treatment of aplastic anemia. Int J Hematol. 2000;72:118-123.
5. Ball SE. The modern management of severe aplastic anaemia. Br J Haematol. 2000;110:41-53.
6. Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med. 1997;336:1365-1372.
7. Sloand E, Maciejewski JP, Kim S, et al. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood. 2000;95:2269-2274.
8. Mathé G, Amiel JL, Schwarzenberg L, et al. Bone marrow graft in man after conditioning by antilymphocytic serum. Br Med J. 1970;2:131-136.
9. Jeannet M, Speck B, Rubinstein A, Pelet B, Wyss M, Kummer H. Autologous marrow reconstitutions in severe aplastic anaemia after ALG pretreatment and HL-A semi-incompatible bone marrow cell transfusion. Acta Haematol. 1976;55:129-139.
10. Speck B, Gluckman E, Haak HL, van Rood JJ. Treatment of aplastic anaemia by antilymphocyte globulin with and without allogeneic bone-marrow infusions. Lancet. 1977;2:1145-1148.
11. Speck B, Gratwohl A, Nissen C, et al. Treatment of severe aplastic anaemia with antilymphocyte globulin or bone-marrow transplantation. Br Med J. 1981;282:860-863.
12. Camitta B, O'Reilly RJ, Sensenbrenner L, et al. Antithoracic duct lymphocyte globulin therapy of severe aplastic anemia. Blood. 1983;62:883-888.
13. Champlin R, Ho W, Gale RP. Antithymocyte globulin treatment in patients with aplastic anemia. N Engl J Med. 1983;308:113-118.
14. Young N, Griffith P, Brittain E, et al. A multicenter trial of antithymocyte globulin in aplastic anemia and related diseases. Blood. 1988;72:1861-1869.
15. Leong KW, Teh A, Bosco JJ, Jayaranee S, Sadat U. Anti-lymphocyte globulin therapy in aplastic anaemia - a university hospital experience. Med J Malaysia. 1995;50:158-161.
16. Preville X, Flacher M, LeMauff B, et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation. 2001;71:460-468.
17. Genestier L, Fournel S, Flacher M, Assossou O, Revillard J-P, Bonnefoy-Berard N. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulin. Blood. 1998;91:2360-2368.
18. Merion RM, Howell T, Bromberg JS. Partial T-cell activation and anergy induction by polyclonal antithymocyte globulin. Transplantation. 1998;65:1481-1489.
19. Teramura M, Kobayashi S, Iwabe K, Yoshinaga K, Mizoguchi H. Mechanism of action of antithymocyte globulin in the treatment of aplastic anaemia: in vitro evidence for the presence of immunosuppressive mechanism. Br J Haematol. 1997;96:80-84.
20. Kook H, Risitano A, Zeng W, et al. Changes in T-cell receptor Vβ-repertoire in aplastic anemia. Effects of different immunosuppressive regimens. Exp Hematol. In press.
21. Myint AA, Malkovska V, Morgan S, Luckit J, Wonke B, Gordon-Smith EC. Antilymphocyte globulin therapy enhances impaired function of natural killer cells and lymphokine activated killer cells in aplastic anemia. Br J Haematol. 1990;75:578-584.
22. Nimer SD, Golde DW, Kwan K, Lee K, Clark S, Champlin R. In vitro production of granulocyte-macrophage colony stimulating factor in aplastic anemia: possible mechanisms of action of antithymocyte globulin. Blood. 1991;78:163-168.
23. Abe T, Matsuoka H, Kojima S, et al. Correlation of response of aplastic anemia patients to antilymphocyte globulin with in vitro lymphocyte stimulatory effect: predictive value of in vitro test for clinical response. Blood. 1991;77:2225-2230.
24. Marsh JC. Hematopoietic growth factors in the pathogenesis and for the treatment of aplastic anemia. Semin Hematol. 2000;37:81-90.
25. + cells in aplastic anaemia and myelodysplasia. Br J Haematol. 2000;108:582-591.
26. Chen G, Kook H, Zeng W, Young NS, Maciejewski JP. Is there a direct effect of antithymocyte globulin on hematopoiesis? Exp Hematol. In press.
27. Bayever E, Champlin R, Ho W, et al. Comparison between bone marrow transplantation and antithymocyte globulin in treatment of young patients with severe aplastic anemia. J Pediatr. 1984;105:920-925.
28. Doney K, Leisenring W, Storb R, Appelbaum FR. Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Ann Intern Med. 1997;126:107-115.
29. Osman I, Koc H, Ismet A, et al. Combined immunosuppressive therapy in aplastic anemia. Indian J Med Res. 1995;102:143-146.
30. Delgado-Lamas JL, Lopez-Karpovitch X, Marin-Lopez A, et al. Low doses of high-potency antithymocyte globulin (ATG) in severe aplastic anemia: experience with the Mexican ATG. Acta Haematol. 1989;81:70-74.
31. Bielory L, Wright R, Nienhuis AW, Young NS, Kaliner MA. Antithymocyte globulin hypersensitivity in bone marrow failure patients. JAMA. 1988;260:3164-3167.
32. Bielory L, Lawley T, Gascon P, Yancey K, Young N, Frank MM. Human serum sickness after equine antithymocyte globulin in patients with bone marrow failure. Medicine (Baltimore). 1988;67:40-57.
33. Shahidi NT, Wang WC, Shurin SB, Finlay JL, Sondel PM, Dinndorf PA. Treatment of acquired aplastic anemia with cyclosporine and androgens. In: Shahidi NT, ed. Aplastic Anemia and Other Bone Marrow Failure Syndromes. London: Springer-Verlag; 1990:155-165.
34. Hinterberger-Fischer M, Hocker P, Lechner K, Seewann H, Hinterberger W. Oral cyclosporin-A is effective treatment for untreated and also for previously immunosuppressed patients with severe bone marrow failure. Eur J Haematol. 1989;43:136-142.
35. Leonard EM, Raefsky E, Griffith P, Kimball J, Nienhuis AW, Young NS. Cyclosporine therapy of aplastic anaemia, congenital and acquired red cell aplasia. Br J Haematol. 1989;72:278-284.
36. Leeksma OC, Thomas LL, Van der Leslie J, Van Oers MH, von dem Borne AE, Goudsmit R. Effectiveness of low dose cyclosporine in acquired aplastic anaemia with severe neutropenia. Neth J Med. 1992;41:143-148.
37. Gluckman E, Esperou-Bourdeau H, Baruchel A, et al. Multicenter randomized study comparing cyclosporine-A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia. Blood. 1992;79:2540-2546.
38. Raghavachar A, Kolbe K, Höffken K, et al. A randomized trial of standard immunosuppression versus cyclosporine and filgastrim in severe aplastic anemia [abstract]. Blood 1997;90(suppl 1):439a.
39. Marsh J, Schrezenmeier H, Marin P, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anemia Working Party. Blood. 1999;93:2191-2195.
40. Zhang N, Shao Z. Efficacy of cyclosporin A in the treatment of aplastic anemia and its mechanism. Zhonghua Xue Ye Xue Za Zhi. 1998;19:218-220.
41. Varma SVN, Malhotra P, Singh S, Sharma DR. Cyclosporin A monotherapy in young Indian aplastic anaemia patients. J Indian Med Assoc. 1999;97:505-506.
42. Maschan A, Bogatcheva N, Kryjanovski O, et al. Results at a single centre of immunosuppression with cyclosporine A in 66 children with aplastic anaemia. Br J Haematol. 1999;106:967-970.
43. Kalechman Y, Sredni B, Caspi RR, Nussenblatt RB. Enhancing effect of cyclosporins A and G on bone marrow colony formation. Exp Hematol. 1990;18:1104-1107.
44. Tong J, Bacigalupo A, Piaggio G, et al. Severe aplastic anemia (SAA): response to cyclosporin A (CyA) in vivo and in vitro. Eur J Haematol. 1991;46:212-216.
45. Hirao A, Kawano Y, Takaue Y. Effects of immunosuppressants, FK506, deoxyspergualin, and cyclosporine A on immature human hematopoiesis. Blood. 1993;81:1179-1183.
46. Nakao S, Takamatsu H, Chuhjo T, et al. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood. 1994;84:4257-4261.
47. Hirose YMY, Ebata K, Okada J, et al. T-cell type acute lymphoblastic leukemia following cyclosporin a therapy for aplastic anemia. Int J Hematol. 2000;73:226-229.
48. Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med. 1991;324:1297-1304.
49. Rosenfeld SJ, Kimball J, Vining D, Young NS. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood. 1995;85:3058-3065.
50. Rosenfeld SJ, Nunez O, Follman D, Young NS. Long-term outcome in severe aplastic anemia is predicted by blood counts after treatment with intensive immunosuppression [abstract]. Blood. 2001;98(suppl 1):749a.
51. Bacigalupo A, Broccia G, Corda G, et al. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA working party. Blood. 1995;85:1348-1353.
52. Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood. 2000;95:1931-1934.
53. Gluckman E, Rokicka-Milewska R, Gordon-Smith EC, et al. Results of a randomized study of glycosylated rHuG-CSF Lenogastrim in severe aplastic anemia [abstract]. Blood 1998;92(suppl 1):376a.
54. Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000;96:2049-2054.
55. Matloub YH, Smith C, Bostrom B, et al. One course versus two courses of antithymocyte globulin for the treatment of severe aplastic anemia in children. J Pediatr Hematol Oncol. 1997;19:110-114.
56. Fuhrer M, Burdach S, Ebell W, et al. Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): the SAA 94 experience. Klin Padiatr. 1998;210:173-179.
57. Tichelli A, Socié G, Henry-Amar M, et al. Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. The European Group for Blood and Marrow Transplantation Several Aplastic Anaemia Working Party. Ann Intern Med. 1999;130:193-201.
58. Marmont AM, Bacigalupo A, van Lint MT, et al. Treatment of severe aplastic anemia with sequential immunosuppression. Exp Hematol. 1983;11:856-865.
59. Schrezenmeier H, Marin P, Raghavachar A, et al. Relapse of aplastic anaemia after immunosuppressive treatment: a report from the European Bone Marrow Transplantation Group SAA Working Party. Br J Haematol. 1993;85:371-377.
60. Di Bona E, Rodeghiero F, Bruno B, et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Br J Haematol. 1999;107:330-334.
61. Crump M, Larratt LM, Maki E, et al. Treatment of adults with severe aplastic anemia: primary therapy with antithymocyte globulin (ATG) and rescue of ATG failures with bone marrow transplantation. Am J Med. 1992;92:596-602.
62. Lawlor ER, Anderson RA, Davis JH, et al. Immunosuppressive therapy: a potential alternative to bone marrow transplantation as initial therapy for acquired severe aplastic anemia in childhood? J Pediatr Hematol Oncol. 1997;19:115-123.
63. Margolis DA, Casper JT. Alternative-donor hematopoietic stem-cell transplantation for severe aplastic anemia. Semin Hematol. 2000;37:43-55.
64. Vassiliou GS, Webb DKH, Pamphilon D, Knapper S, Veys PA. Improved outcome of alternative donor bone marrow transplantation in children with severe aplastic anaemia using a conditioning regimen containing low-dose total body irradiation, cyclophosphamide and Campath. Br J Haematol. 2001;114:701-705.
65. Kojima S, Inaba J, Yoshimi A, et al. Unrelated donor marrow transplantation in children with severe aplastic anaemia using cyclophosphamide, anti-thymocyte globulin and total body irradiation. Br J Haematol. 2001;114:706-711.
66. Deeg HJ, Seidel K, Casper J, et al. Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy. Biol Blood Marrow Transplant. 1999;5:243-252.
67. Grima KM. Therapeutic apheresis in hematological and oncological diseases. J Clin Apheresis. 2000;15:28-52.
68. Ito T, Hiraiwa M, Ishikawa Y, et al. Lymphocytapheresis in a patient with severe aplastic anemia. Acta Haematol. 1988;80:167-170.
69. Morales-Polanco MR, Sanchez-Valle E, Guerrero-Rivera S, Gutierrez-Alamillo L, Delgado-Marquez B. Treatment results of 23 cases of severe aplastic anemia with lymphocytapheresis. Arch Med Res. 1997;28:85-90.
70. Young NS, Klein HG, Griffith P, Nienhuis AW. A trial of immunotherapy in aplastic anemia and pure red cell aplasia. J Clin Apheresis. 1983;1:95-103.
71. Bacigalupo A, Podesta' M, van Lint MT, et al. Severe aplastic anaemia: correlation of in vitro tests with clinical response to immunosuppression in 20 patients. Br J Haematol. 1981;47:423-433.
72. Doney K, Pepe M, Storb R, et al. Immunosuppressive therapy of aplastic anemia: results of a prospective, randomized trial of antithymocyte globulin (ATG), methylprednisolone, and oxymetholone to ATG, very high-dose methylprednisolone, and oxymetholone. Blood. 1992;79:2566-2571.
73. Schwinger W, Urban C, Lackner H, Mache C. Treatment of aplastic anemia with a monoclonal antibody directed against the interleukin-2 receptor. Ann Hematol. 1993;66:181-184.
74. Jansen J, Gratama JW, Zwaan FE, Simonis RFA. Therapy with monoclonal antibody OKT3 in severe aplastic anemia. Exp Hematol. 1984;12(suppl 15):46-47.
75. Doney K, Martin P, Storb R, et al. A randomized trial of antihuman thymocyte globulin versus murine monoclonal antihuman T-cell antibodies as immunosuppressive therapy for aplastic anemia. Exp Hematol. 1985;13:520-524.
76. Willis F, Marsh JC, Bevan DH, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001;114:891-898.
77. Thomas ED, Storb R, Giblett ER, et al. Recovery from aplastic anemia following attempted marrow transplantation. Exp Hematol. 1976;4:97-102.
78. Territo MC. Autologous bone marrow repopulation following high dose cyclophosphamide and allogeneic marrow transplantation in aplastic anemia. Br J Haematol. 1977;36:305-311.
79. Tisdale JF, Dunn DE, Maciejewski J. Cyclophosphamide and other new agents for the treatment of severe aplastic anemia. Semin Hematol. 2000;37:102-109.
80. Baran DT, Griner PF, Klemperer MR. Recovery from aplastic anemia after treatment with cyclophosphamide. N Engl J Med. 1976;295:1522-1523.
81. Griner PF. A survey of the effectiveness of cyclophosphamide in patients with severe aplastic anemia. Am J Hematol. 1980;8:55-60.
82. Brodsky RA, Sensenbrenner LL, Jones RJ. Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation. Blood. 1996;87:491-494.
83. Brodsky RA, Sensenbrenner LL, Smith BD, et al. Durable treatment-free remission after high dose cyclophosphamide therapy for previously severe aplastic anemia. Ann Intern Med. 2001;135:477-483.
84. Tisdale JF, Dunn DE, Geller NL, et al. High-dose cyclophosphamide in severe aplastic anemia: a randomized trial. Lancet. 2000;356:1554-1559.
85. Jaime-Perez JC, Gonzalez-Llano O, Gomez-Almaguer D. High-dose cyclophosphamide in the treatment of severe aplastic anemia in children. Ann Hematol. 2001;66:71.
86. Li Z, Yin S, Xie S, Ma L, Nie D, Xsu L. Treatment of severe aplastic anemia using high-dose cyclophosphamide in China. Haematologica. 2000;85:1-2.
87. Tisdale JF, Maciejewski JP, Nunez O, Rosenfeld SJ, Young NS. A randomized trial comparing antithymocyte globulin and cyclosporin to cyclophosphamide and cyclosporin for initial treatment in severe aplastic anemia: results of long-term follow-up [abstract]. Blood. 2001;98(Part 1):223a.
88. Heimpel H. Aplastic anemia before bone marrow transplantation and antilymphocyte globulin. Acta Haematol. 2000;103:11-15.
89. Maciejewski JP, Rivera C, Dunn D, Young NS. Clinical features of the relationship between aplastic anemia and paroxysmal nocturnal hemoglobinuria. Br J Haematol. 2001;115:1015-1021.
90. Socie G, Rosenfeld S, Frickhofen N, Gluckman E, Tichelli A. Late clonal diseases of treated aplastic anemia. Semin Hematol. 2000;37:91-101.
91. Socié G, Henry-Amar M, Bacigalupo A, et al. Malignant tumors occurring after treatment of aplastic anemia. N Engl J Med. 1993;329:1152-1157.
92. Maciejewski JP, Risitano AM, Nunez O, Young NS. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood. In press.
93. Mikhailova N, Sessarego M, Fugazza G, et al. Cytogenetic abnormalities in patients with severe aplastic anemia. Haematologica. 1996;81:418-422.
94. Arranz R, Otero MJ, Ramos R, et al. Clinical results in 50 multiply transfused patients with severe aplastic anemia treated with bone marrow transplantation or immunosuppressive therapy. Bone Marrow Transplant. 1994;13:383-387.
95. Paquette RL, Tebyani N, Frane M, et al. Long-term outcome of aplastic anemia in adults treated with antithymocyte globulin: comparison with bone marrow transplantation. Blood. 1995;85:283-290.
96. Gillio AP, Boulad F, Small TN, et al. Comparison of long-term outcome of children with severe aplastic anemia treated with immunosuppression versus bone marrow transplantation. Biol Blood Marrow Transplant. 1997;5:18-24.
97. Fouladi M, Herman R, Roland-Grinton M, et al. Improved survival in severe acquired aplastic anemia of childhood. Bone Marrow Transplant. 2000;26:1149-1156.
98. Bacigalupo A, Brand R, Oneto R, et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy-the European Group for Blood and Marrow Transplantation experience. Semin Hematol. 2000;37:69-80.
99. Fisch P. Pure red cell aplasia. Br J Haematol. 2000;111:1010-1022.
100. Abkowitz JL. Acquired pure red cell aplasia: physiology and therapy. In: Schechter GP, Berliner N, Telen MJ, eds. Hematology 2000. Washington, DC: American Society of Hematology; 2000:24-27.
101. Lacy MQ, Kurtin PJ, Tefferi A. Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood. 1996;87:3000-3006.
102. Handgretinger R, Geiselhart A, Moris A. Pure red cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors. N Engl J Med. 2001;340:278-284.
103. Go RS, Li C-Y, Tefferi A, Phyliky RL. Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes. Blood. 2001;98:483-485.
104. Yamada O, Mizoguchi H, Oshimi K. Cyclophosphamide therapy for pure red cell aplasia associated with granular lymphocyte-proliferative disorders. Br J Haematol. 1997;97:392-399.
105. Yamada O, Motoji T, Mizoguchi H. Selective effect of cyclosporine monotherapy for pure red cell aplasia not associated with granular lymphocyte-proliferative disorders. Br J Haematol. 1999;106:371-376.
106. + T cell large granular lymphocytosis: dependence on cyclosporin A therapy. Acta Haematol. 1998;100:207-210.
107. Yamada O. Clonal T cell proliferation in patients with pure red cell aplasia. Leuk Lymphoma. 1999;35:69-82.
108. Abkowitz JL, Powell JS, Nakamura JM, Kadin ME, Adamson JW. Pure red cell aplasia: response to therapy with anti-thymocyte globulin. Am J Hematol. 1986;23:363-371.
109. Mangan KF, Shadduck RK. Successful treatment of chronic refractory pure red cell aplasia with antithymocyte globulin: correlation with in vitro erythroid culture studies. Am J Hematol. 1984;17:417-426.
110. Kwong YL, Wong KF. Association of pure red cell aplasia with T large granular lymphocyte leukaemia. J Clin Pathol. 1998;54:672-675.
111. Ustun C, Karaveliogiu D, Ilhan O, Aydintug O, Beksac M. A case report of a patient who has pure red cell aplasia and rheumatoid arthritis. Int J Hematol. 1997;66:505-512.
112. Ueda K, Matsubara A, Kizuki N, Sato Y, Oka Y. Successful treatment of acquired pure red cell aplasia and acquired amegakaryocytic thrombocytopenia with anti-thymocyte globulin. Ann J Hematol. 2001;66:154-155.
113. Ahn JH, Lee KH, Lee JH, et al. A case of refractory idiopathic pure red cell aplasia responsive to fludarabine treatment. Br J Haematol. 2001;112:527-529.
114. Manoharan A, Williams NT, Sparrow R. Acquired amegakaryocytic thrombocytopenia: report of a case and review of literature. Q J Med. 1989;70:243-252.
115. Rosenfeld S. Amegakaryocytic thrombocytopenia. In: Young NS, ed. The Bone Marrow Transplantation Syndromes. Philadelphia, Pa: W.B. Saunders; 2000:183-186.
116. Trimble MS, Glynn MF, Brain MC. Amegakaryocytic thrombocytopenia of 4 years duration: success treatment with antithymocyte globulin. Am J Hematol. 1991;37:126-127.
117. Spath-Schwalbe E, Arnold R, Flath B, Possinger K. Red cell aplasia and megakaryocytic hypoplasia with elevated counts of CD8-positive lymphocytes after resection of a thymoma responding to cyclosporine. Ann Hematol. 1998;76:51-52.
118. Leach J, Hussein KK, George JN. Acquired pure megakaryocytic aplasia report of two cases with long-term responses to antithymocyte globulin and cyclosporine. Am J Hematol. 1999;62:115-117.
119. Litzow MR, Kyle RA. Multiple responses of aplastic anemia to low-dose cyclosporine therapy despite development of a myelodysplastic syndrome. Am J Hematol. 1989;32:226-229.
120. Young NS, Barrett AJ. Immune modulation of myelodysplasia: rationale and therapy. In: Bennett JM, ed. The Myelodysplastic Syndromes: Pathobiology and Clinical Management. New York: Marcel Dekker; in press, 2002.
121. Hamblin T. Immunologic abnormalities in myelodysplastic syndromes. Hematol Oncol Clin North Am. 1992;6:571-586.
122. Saunthararajah Y, Molldrem JJ, Rivera M, et al. Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features. Br J Haematol. 2001;112:195-200.
123. Tichelli A, Gratwohl A, Wuersch A, Nissen C, Speck B. Antilymphocyte globulin for myelodysplastic syndrome? Br J Haematol. 1988;68:139-140.
124. Miescher PA, Favre H, Beris P. Autoimmune myelodysplasias. Semin Hematol. 1991;28:322-329.
125. Biesma DH, van den Tweel JG, Verdonck LF. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer. 1997;79:1548-1551.
126. Molldrem J, Rivera M, Bahceci E, et al. Treatment of bone marrow failure of myelodysplastic syndrome with antithymocyte globulin. Ann Intern Med. In press.
127. Jonasova A, Neuwirtova R, Cermak J, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol. 1998;200:304-309.
128. Shimamoto T, Iguchi T, Ando K, et al. Successful treatment with cyclosporin A for myelodysplastic syndrome with erythroid hypoplasia associated with T-cell receptor gene rearrangements. Br J Haematol. 2001;114:358-361.
129. Tamayose K, Sugimoto K, Ando M, Oshimi K. Disappearance of chromosomal abnormalities and recovery of hematopoiesis after immunosuppressive therapy for hypoplastic refractory anemia with excess of blasts. Blood. 2001;97:2524.